Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma.
about
Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literatureFeminizing adrenocortical tumors: Literature review.The efficacy of radiation therapy in adrenocortical carcinoma: A propensity score analysis of a population-based studyTranscutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome.CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma.Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.Understanding primary aldosteronism: impact of next generation sequencing and expression profiling.Emerging therapy for adrenocortical carcinoma.Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States.Adrenocortical cancer: mortality, hormone secretion, proliferation and urine steroids - experience from a single centre spanning three decades.Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progressionAdrenocortical carcinoma: modern management and evolving treatment strategies.Clinicopathological Features Associated With the Prognosis of Patients With Adrenal Cortical Carcinoma: Usefulness of the Ki-67 Index.Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes.Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Long-Term Survival.Outcomes after resection of cortisol-secreting adrenocortical carcinomaNomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma.The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.Diagnosis, treatment and outcome of adrenocortical cancer.Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.Unraveling the expression of the oncogene YAP1, a Wnt/beta-catenin target, in adrenocortical tumors and its association with poor outcome in pediatric patients.Pediatric adrenocortical neoplasms: can imaging reliably discriminate adenomas from carcinomas?Adrenocortical carcinoma: patterns of care and role of adjuvant radiation therapy-a population-based study and review of the literature.Primary site surgery for metastatic adrenocortical carcinoma improves survival outcomes: an analysis of a population-based database.Overexpression of HSD17B4 exerts tumor suppressive function in adrenocortical carcinoma and is not associated with hormone excess.Prognostic Factors of Adrenocortical Carcinoma: An Analysis of the Surveillance Epidemiology and End Results (SEER) DatabaseA Case Report of Bilateral Sarcomatoid Carcinoma of Adrenal Glands With Adrenal Insufficiency.ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing's syndrome.Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.Drug repurposing using high-throughput screening identifies a promising drug combination to treat adrenocortical carcinomaRole of Mitotane in Adrenocortical Carcinoma - Review and State of the artTherapeutic Targets for Adrenocortical Carcinoma in the Genomics Era
P2860
Q27021404-F14704FF-D0AF-4AFC-8308-03E9861DE7C5Q30487912-35BD93D7-A255-401D-8C3A-DFBF06B56D4EQ33627211-4B47D6DB-62DE-40A4-8A9C-19634BBAF9C2Q33896706-2FDF4F4A-2ADE-470C-B4FF-5E55F3915EADQ34075752-C8ED250B-6402-4552-A143-01707503B16DQ34677263-F5DDEB48-42BD-4BB8-BB8B-DDABDA3DCD10Q34850075-E601E08F-4543-4629-9363-BFAAE6F813E9Q35018399-45FD4F17-3323-4D07-97F4-8066565D7ECFQ35889904-796F8081-C315-4DDF-AC2F-44977D59FF79Q35960108-CCC287B4-BA25-4D66-813B-6A01C52BAE09Q36772101-051DAF23-CF90-4312-80C4-ABC4C9615F80Q36908711-3BEF9BE7-066B-4430-B4C8-92699979BF14Q36992917-27668FD5-5AE9-4B09-B289-8CEE534D5DD1Q37114016-9904E5E4-869B-4067-93D3-1AA5058BC1B9Q37119581-5252E75D-92C0-49E9-B98E-024FDEB520E5Q37119585-629D4E9C-7F5A-43A7-AA12-D981F4274C54Q37119591-05A8CF8A-38BA-4D4B-8F40-570E15F0712CQ37140005-BAE09FA8-D2C4-43C8-A69F-2DD4D8D0F66EQ37452556-C7E7396C-6596-4ACA-BE37-E518E80B57DFQ38358503-D3507E3C-AFC6-4B2B-B381-D6CB28E67D2DQ38706908-87145A36-9800-4975-89D4-570DFE39EA0BQ38713191-93EFF84A-BBDD-4DF1-9771-579EE4F71610Q38814667-61822578-EB83-4D51-8E66-9E633791BF13Q41187237-986A14A5-8D9E-47AD-8FC5-23C875607D0FQ41559524-CBD5788D-341E-4CC6-B991-DB5EA522AA12Q47102243-C570CFA7-79F1-457E-8828-AC75CC93886AQ49207970-FF170B26-8F1E-47BE-BF8D-44243B1F5710Q50088488-AC9AFEA7-81C9-462F-B06A-05D50F61DAC2Q52973231-AFE09C15-40CE-4E88-9DD8-7CF2AA950308Q55316663-7C1E2019-18B6-4327-BEB6-EFA0087CA5B9Q55399185-025E6024-2328-4FA5-97D6-6DEC0491424AQ57117195-CE1FD772-4D12-4183-A2CC-63F068634CF6Q57822726-A60E3D04-0305-4B5B-A840-A1C46E589208Q58550571-21D07414-D904-4006-A6A2-98C366C79944
P2860
Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adjuvant therapies and patient ...... with adrenocortical carcinoma.
@en
Adjuvant therapies and patient ...... with adrenocortical carcinoma.
@nl
type
label
Adjuvant therapies and patient ...... with adrenocortical carcinoma.
@en
Adjuvant therapies and patient ...... with adrenocortical carcinoma.
@nl
prefLabel
Adjuvant therapies and patient ...... with adrenocortical carcinoma.
@en
Adjuvant therapies and patient ...... with adrenocortical carcinoma.
@nl
P2093
P2860
P356
P1476
Adjuvant therapies and patient ...... with adrenocortical carcinoma.
@en
P2093
Aaron Sabolch
Andrew R Williams
Barbra S Miller
Gary D Hammer
Shruti Jolly
Tobias Else
P2860
P304
P356
10.1210/JC.2013-2856
P407
P577
2013-12-03T00:00:00Z